Details

Autor(en) / Beteiligte

• Yang, Zhe
• Gao, Di
• Zhao, Jing
• Yang, Gaojie
• Guo, Ming
• Wang, Ying
• Ren, Xuechun
• Kim, Jong Seung
• Jin, Lin
• Tian, Zhongmin
• Zhang, Xingcai

Titel

Thermal immuno-nanomedicine in cancer

Ist Teil von

• Nature reviews. Clinical oncology, 2023-02, Vol.20 (2), p.116-134

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Immunotherapy has revolutionized the treatment of patients with cancer. However, promoting antitumour immunity in patients with tumours that are resistant to these therapies remains a challenge. Thermal therapies provide a promising immune-adjuvant strategy for use with immunotherapy, mostly owing to the capacity to reprogramme the tumour microenvironment through induction of immunogenic cell death, which also promotes the recruitment of endogenous immune cells. Thus, thermal immunotherapeutic strategies for various cancers are an area of considerable research interest. In this Review, we describe the role of the various thermal therapies and provide an update on attempts to combine these with immunotherapies in clinical trials. We also provide an overview of the preclinical development of various thermal immuno-nanomedicines, which are capable of combining thermal therapies with various immunotherapy strategies in a single therapeutic platform. Finally, we discuss the challenges associated with the clinical translation of thermal immuno-nanomedicines and emphasize the importance of multidisciplinary and inter-professional collaboration to facilitate the optimal translation of this technology from bench to bedside. Immunotherapies have dramatically improved the outcomes of a subset of patients with advanced-stage cancers. Nonetheless, most patients will not respond to these agents and adverse events can be severe. In this Review, the authors describe the potential to address these challenges by combining immunotherapies with currently available thermal therapies as well as by using thermal immuno-nanomedicines. Key points Immunotherapy has revolutionized cancer therapy, and the clinical effectiveness of approaches such as immune-checkpoint inhibitors and cellular immunotherapies has created substantial improvements in outcomes. Thermal therapies designed to deliver local hyperthermia can promote antitumour immunity via the induction of immunogenic cell death following tumour ablation and by reprogramming the tumour microenvironment. Several early-phase trials combining thermal therapies with immunotherapy are either ongoing or completed, and some have provided encouraging results that support the further clinical development of combined thermal therapy–immunotherapy approaches. Thermal immuno-nanomedicines are thermal therapies that also incorporate immunotherapies within a single nanoparticle, potentially enabling simultaneous activity and synergy between these two modalities. Preclinical evidence suggests that thermal immuno-nanomedicines provide a promising cancer therapeutic strategy; however, coordinated efforts from multidisciplinary teams of experts will be required to drive the clinical translation of this technology.